A Comparison Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Congenital Factor Vii Deficiency

A Comparison Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Congenital Factor Vii Deficiency Publisher Pubmed

Faranoush M¹ ; Abolghasemi H² ; Toogeh G³ ; Karimi M⁴ ; Eshghi P² ; Managhchi M³ ; Hoorfar H⁵ ; Dehdezi BK⁶ ; Mehrvar A⁷ ; Khoeiny B⁸ ; Kamyar K⁸ ; Heshmat R³ ; Baghaeipour MR⁹ ; Mirbehbahani NB¹⁰ Show All Authors

Faranoush M¹
Abolghasemi H²
Toogeh G³
Karimi M⁴
Eshghi P²
Managhchi M³
Hoorfar H⁵
Dehdezi BK⁶
Mehrvar A⁷
Khoeiny B⁸
Kamyar K⁸
Heshmat R³
Baghaeipour MR⁹
Mirbehbahani NB¹⁰
Fayazfar R¹¹
Ahmadinejad M¹²
Naderi M¹³

Show Affiliations

1. High Institute of Research, Iranian Blood Transfusion Organization, Iran University of Medical Sciences, Rasool Akram Hospital, Tehran, Iran
2. Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Tehran University of Medical Sciences, Thrombosis and Hemostasis Research Center, Tehran, Iran
4. Shiraz University of Medical Sciences, Shiraz, Iran
5. Isfahan University of Medical Sciences, Isfahan, Iran
6. Ahwaz University of Medical Sciences, Ahwaz, Iran
7. MAHAK Childrens Hospital, Tehran, Iran
8. Aryogen Zist Darou Company, Karaj, Iran
9. Iranian Comprehensive Hemophilia Care Center, Tehran, Iran
10. Golestan University of Medical Sciences, Gorgan, Iran
11. Kerman University of Medical Sciences, Kerman, Iran
12. IBTO, Tehran, Iran
13. Zahedan University of Medical Sciences, Ahwaz, Iran

Source: Clinical and Applied Thrombosis/Hemostasis Published:2015

Abstract

In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII) deficiency, patients received either agent at 30 1/4g/kg, intravenously per week for 4 weeks, in a randomized fashion. The primary aim was to compare FVII:coagulation activity (FVII:C), 20 minutes after recombinant activated FVII (rFVIIa) injection, in the 2 groups. A secondary measure was self-reported bleeding. The median interquartile baseline range of the plasma level of activated FVII (FVIIa) activity in the 2 groups was 1.6 (1.1-14.0) IU/dL and 5.0 (1.1-25.5) IU/dL. All patients achieved levels of FVIIa (FVII:C) >30 IU/dL, 20 minutes after the injection of rFVIIa. Bleeding was similar between the 2 groups, with a comparable decrease in severity and frequency compared to the last month prior to treatment. AryoSeven is similar to NovoSeven in increasing postinjection FVIIa activity as well as in clinical safety and efficacy. © The Author(s) 2014.

2. Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor Vii (Aryoseven™) and Activated Prothrombin Complex Concentrates (Feiba™) to Treat Hemophilia a Patients With Inhibitors in Iran, Iranian Journal of Pharmaceutical Research (2016)

3. A Randomized, Two-Armed, Double-Blind, Single-Dose, Cross-Over, Bioequivalence Clinical Trial to Compare Pharmacokinetic Parameters and Safety of Recombinant Human Factor Viii With Fc Fusion Produced by Aryogen Pharmed Company Versus Elocta® (Reference Product) in Previously Treated Patients With Severe Haemophilia A, Annals of Hematology (2025)

4. The First Discrete Choice Experiment on Usage of Bypassing Agents in Hemophilic Patients in Iran, Iranian Journal of Blood and Cancer (2016)

5. Comparative Evaluation of the Safety and Efficacy of Recombinant Fviii in Severe Hemophilia a Patients, Journal of Pharmacopuncture (2018)

6. Impact of Factor Viii and Von Willebrand Factor Plasma Levels on Cerebral Venous and Sinus Thrombosis: Are They Independent Risk Factors?, European Neurology (2011)

Experts (# of related papers)

View all Related Experts

Majid Ghanavat (1)

Mohammad Saadatnia (1)

Style	Citing Format
MLA	Faranoush M, et al.. "A Comparison Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Congenital Factor Vii Deficiency." Clinical and Applied Thrombosis/Hemostasis, vol. 21, no. 8, 2015, pp. 724-728.
APA	Faranoush M, Abolghasemi H, Toogeh G, Karimi M, Eshghi P, Managhchi M, Hoorfar H, Dehdezi BK, Mehrvar A, Khoeiny B, Kamyar K, Heshmat R, Baghaeipour MR, Mirbehbahani NB, Fayazfar R, Ahmadinejad M, Naderi M (2015). A Comparison Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Congenital Factor Vii Deficiency. Clinical and Applied Thrombosis/Hemostasis, 21(8), 724-728.
Chicago	Faranoush M, Abolghasemi H, Toogeh G, Karimi M, Eshghi P, Managhchi M, Hoorfar H, et al.. "A Comparison Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Congenital Factor Vii Deficiency." Clinical and Applied Thrombosis/Hemostasis 21, no. 8 (2015): 724-728.
Harvard	Faranoush M et al. (2015) 'A Comparison Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Congenital Factor Vii Deficiency', Clinical and Applied Thrombosis/Hemostasis, 21(8), pp. 724-728.
Vancouver	Faranoush M, Abolghasemi H, Toogeh G, Karimi M, Eshghi P, Managhchi M, et al.. A Comparison Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Congenital Factor Vii Deficiency. Clinical and Applied Thrombosis/Hemostasis. 2015;21(8):724-728.
BibTex	@article{ author = {Faranoush M and Abolghasemi H and Toogeh G and Karimi M and Eshghi P and Managhchi M and Hoorfar H and Dehdezi BK and Mehrvar A and Khoeiny B and Kamyar K and Heshmat R and Baghaeipour MR and Mirbehbahani NB and Fayazfar R and Ahmadinejad M and Naderi M}, title = {A Comparison Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Congenital Factor Vii Deficiency}, journal = {Clinical and Applied Thrombosis/Hemostasis}, volume = {21}, number = {8}, pages = {724-728}, year = {2015} }
RIS	TY - JOUR AU - Faranoush M AU - Abolghasemi H AU - Toogeh G AU - Karimi M AU - Eshghi P AU - Managhchi M AU - Hoorfar H AU - Dehdezi BK AU - Mehrvar A AU - Khoeiny B AU - Kamyar K AU - Heshmat R AU - Baghaeipour MR AU - Mirbehbahani NB AU - Fayazfar R AU - Ahmadinejad M AU - Naderi M TI - A Comparison Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Congenital Factor Vii Deficiency JO - Clinical and Applied Thrombosis/Hemostasis VL - 21 IS - 8 SP - 724 EP - 728 PY - 2015 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract